MedTrace Logo

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

NCT02656485 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-04-05

Study results available
· View outcomes & findings →

Summary

This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

B244

10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

DRUG

Placebo

10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Sponsors & Collaborators

  • AOBiome LLC

    lead INDUSTRY

Principal Investigators

  • Peter Hino, MD · Stephens Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-05
Primary Completion
2016-03-01
Completion
2016-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656485 on ClinicalTrials.gov